Previous Close | 9.01 |
Open | 9.00 |
Bid | 8.86 x 100 |
Ask | 8.92 x 100 |
Day's Range | 8.77 - 9.00 |
52 Week Range | 8.21 - 12.03 |
Volume | |
Avg. Volume | 366,513 |
Market Cap | 428.666M |
Beta (5Y Monthly) | 0.37 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.00 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for TBPH
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The life of a bearish speculator can be dangerous and that’s part of the appeal of short-squeeze stocks: you can make life miserable for those attempting to cynically extract profits from others’ misery. At the most elemental level, I suppose it’s like watching a lion eating a safari hunter. Perhaps it’s a bit irrational but I believe I speak for most of us: we’d root for the lion and feel that the hunter received poetic justice. It’s what the kids call fool around and find out or FAFO. And that
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript February 26, 2024 Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.04. TBPH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, good afternoon. I’d […]